作为国内食品安全检测领域的领军企业，易瑞生物在研发方面的投入保持较强劲态势。2025年前三季度，公司研发费用投 入达3081.93万元，同比增长7.00%，研发投入占营收比例16.60%。 本报讯 （记者李昱丞）10月27日晚间，食品安全快检企业深圳市易瑞生物技术股份有限公司（以下简称"易瑞生物"）发布 2025年第三季度报告。报告显示，公司主营业务扩张，持续巩固食安领域护城河，盈利能力提升，前三季度扣非后归母净利润 扭亏为盈。 易瑞生物2025年前三季度实现营业收入1.86亿元，同比增长17.45%，归母净利润为1802.30万元。其中，第三季度单季表现 尤为突出，实现营业收入7634.62万元，同比增长40.34%。 公司前三季度扣非后归母净利润扭亏为盈，达到372.85万元；第三季度单季扣非后归母净利润达578.60万元。 公司积极推进食品安全全自动数智化检测平台建设，前瞻性布局化学发光技术平台，引领行业检测模式的重构。通过"自 动数智化+技术平台化"双轮驱动，易瑞生物不断巩固技术优势，为长期发展注入动能。 （编辑 郭之宸） ...

Group 1 - The National Healthcare Security Administration (NHSA) has held five meetings focused on "supporting innovative drugs and medical devices," emphasizing the policy direction of "genuine support for innovation, supporting true innovation, and supporting differentiated innovation," while rejecting pseudo-innovation and inward competition [1] - The meetings cover a comprehensive policy system from the research and development project initiation of innovative drugs and devices, value assessment, medical insurance access, to capital support, aiming to create a collaborative effort to promote industry development [1] - The policy advancement is expected to stimulate industry innovation vitality and accelerate industrial upgrading, with domestic companies possessing independent innovation capabilities likely to benefit in the long term [1] Group 2 - The ChiNext Medical ETF (159377) tracks the Innovative Medical Index (399275), which can experience daily fluctuations of up to 20%. This index selects listed companies involved in biomedicine and medical devices from the ChiNext market as sample securities [1] - The Innovative Medical Index focuses on reflecting the overall performance of the healthcare industry in China's ChiNext market, with constituent stocks characterized by high growth potential and significant volatility [1]